Clinical Trial Reporting Would Expand To Unapproved Drugs Under FDA, NIH Reg
Executive Summary
Advocates may press for even more disclosures to better understand economics of clinical research.
You may also be interested in...
HHS ClinicalTrials.Gov Rule Details Penalties For Failure To Submit
The US department's final rule for disclosing summary results to clinical trials extends to early studies of unapproved products.
Clinical Trial Disclosure Rule Warns Of Legal Penalties For Failure To Submit
Final rule for submitting summary results to ClinicalTrials.gov extends to early studies of unapproved products.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.